Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonia

Anna Modoni 1*, Adele D’Amico 2, Guido Primiano 1, Fiorentino Capozzoli 3, Jean-François Desaphy 4 and Mauro Lo Monaco 1,5

1 Department of Geriatric, Neurologic, Orthopedics and Head-Neck Science, Area of Neuroscience, Institute of Neurology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. 6 Department of Neuromuscular and Neurodegenerative Diseases, Laboratory of Molecular Medicine, Department of Neurosciences, Bambino Gesù Children’s Hospital, Rome, Italy. 7 Department of Neuromuscular and Neurodegenerative Diseases, Laboratory of Molecular Medicine, Department of Neurosciences, Bambino Gesù Children’s Hospital, Rome, Italy. 8 Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Polyclinic, Bari, Italy. 9 MIA Onlus (“Miotonici in Associazione”), Portici, Italy

Objective: The aim of our study was to evaluate the long-term efficacy and safety of mexiletine in 112 patients affected by genetically confirmed non-dystrophic myotonia. The study was performed at the Neurophysiologic Division of Fondazione Policlinico Universitario A. Gemelli Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome and the Children’s Hospital Bambino Gesù, Rome.

Methods: The treatment was accepted by 59 patients according to clinical severity, individual needs, and concerns about a chronic medication. Forty-three patients were affected by recessive congenital myotonia, 11 by sodium channel myotonia, and five by dominant congenital myotonia. They underwent clinical examination before and after starting therapy, and Electromyography (EMG). A number of recessive myotonia patients underwent a protocol of repetitive nerve stimulations, for detecting and quantifying the transitory weakness, and a modified version of the Timed Up and Go test, to document and quantify the gait impairment.

Results: Treatment duration ranged from 1 month to 20 years and the daily dosages in adults ranged between 200 and 600 mg. No patient developed cardiac arrhythmias causing drug discontinuation. Mexiletine was suspended in 13 cases (22%); in three patients, affected by Sodium Channel myotonia, because flecainide showed better efficacy; in one patient because of a gastric cancer antecedent treatment; in four patients because of untreatable dyspepsia; and five patients considered the treatment not necessary.

Conclusions: In our experience, mexiletine is very useful and not expensive. We did not observe any hazarding cardiac arrhythmias. Dyspepsia was the most frequent dose-limiting side effect.

Keywords: mexiletine, non-dystrophic myotonia, treatment tolerability, adverse effects, genotype-phenotype correlations
INTRODUCTION

Non-dystrophic myotonias are due to loss-of-function mutations in the voltage-gated chloride CIC-1 channel, encoded by the CLCN1 gene, or gain-of-function mutations in the voltage-gated sodium Nav1.4 channel, encoded by the SCN4A gene (1–3). These are rare disorders, with a prevalence of < 1:100,000, characterized by clinical and electrophysiological myotonias, which is lifelong and impact quality of life. Today the drug of choice for treating myotonia is mexiletine, whatever the culprit gene (4–6). Mexiletine is a non-selective voltage-gated sodium channel blocker that belongs to the Class IB anti-arrhythmic drugs (6, 7).

In Italy, as in many other European countries, mexiletine was no longer available on the market, but since 2010 it can be obtained from the Military Chemical Pharmaceutical Plant of Florence (Stabilimento Chimico Farmaceutico Militare di Firenze) as a "named-patient" drug. Costs are entirely covered by the Italian National Health System.

Because of its activity on the heart, patients usually consider mexiletine a risky drug with potential cardiac side effects, a consideration that is often shared by primary care physicians despite literature data showing the absence of any significant change in Electrocardiogram (ECG) parameter or serious adverse cardiac event during long-term follow-up (6). On the other hand, some common non-cardiac side effects such as dyspepsia, nausea, heartburn, lightheadedness, and others are often dose-limiting (7).

The aims of this study were to evaluate the long-term efficacy and safety of mexiletine in 59 patients affected by non-dystrophic myotonias. The patients underwent clinical and neurophysiologic examination before and after treatment.

METHODS

Between 1999 and 2019, 112 patients affected by non-dystrophic myotonias have been followed at the Neurophysiologic Division of Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, and the Children's Hospital Bambino Gesù, Rome. Among these patients, 59 (33 males and 26 females) have accepted the suggestion of a symptomatic treatment and have been treated with mexiletine. Follow-up visits of treated patients have been scheduled every 6 months during the first year after starting treatment and then every year. Daily dosage and any side effects have been reported in each medical record.

Clinical Examination

All the patients have undergone an in-depth clinical assessment. Clinical examination included searching for action myotonia wrist, eyelid, and tongue muscles, as well as percussion myotonia in the upper limbs (extensor digitorum communis) and lower limbs (rectus femoris). In particular, the presence and duration of the myotonic phenomenon at wrist and eyelid was evaluated after a three-second forced closure. This maneuver was repeated five times subsequently in order to detect any paradoxical myotonia. Before looking for eyelid myotonia, the presence of lid-lag phenomenon was verified in patients lying in a supine position.

The presence of transitory weakness was verified by asking the patient to exert a maximal voluntary contraction of biceps brachii: as soon as the muscle reached its peak force, a quick exhaustion developed, lasting until the muscle was allowed to relax and contract for four or five times. The muscle could fully recover only after such a warming up maneuver.

In addition, we examined the lower limbs motor difficulties that may occur due to either myotonia or transitory weakness by using a modified version of the Timed Up and Go test (8, 9). Specifically, patients were asked to run around a chair three times, first after rest (i.e., 5 min of sitting on the chair in a complete relaxed position, with extended legs) and then after warming up. We calculated the percentage difference between the time spent to perform the test at rest and after warming up as follows: (time at rest – time after warm-up) × 100/time at rest (chair test normal values: mean: 4.7%; SD: 8.0; n = 22; cut-off: 21%).

We also paid attention to muscle hypertrophy (grading 1–4), especially in neck and shoulders for NaM patients and lower limbs for MC patients.

Neurophysiological Examination

All the patients were examined by needle EMG on extensor digitorum communis in order to detect myotonic discharges.

Clinical assessment oriented neurophysiologic evaluations, since different electromyographic patterns correlate with different pathogenic mechanism of muscle channelopathies (10–12). In particular, in our cohort of patients we performed the low-rate prolonged repetitive nerve stimulations (3Hz-RNS) to detect and quantify the transitory weakness of the intrinsic muscles of the hand (12). This test showed good tolerability and reproducibility, being performed before and after treatment. In short, the wrist ulnar nerve was stimulated at 3 Hz and the compound muscle action potential (CMAP) recorded from the adductor digiti quinti muscle. In some individuals, a transient depression of the CMAP amplitude developed during stimulation, reaching the nadir within about 30 s and recovering within 1 min of stimulation (12, 13). This transitory CMAP depression is considered the neurophysiological counterpart of the transitory weakness (14, 15).

Genetic Analysis

Genetic analyses were performed based on clinical and electrophysiological findings. In presence of a prevalent neck or shoulder muscle hypertrophy together with eyelid myotonia, especially when paradoxical, strabismus, transitory diplopia, and/or referred adynamia, the mutational analysis was first on SCN4A. When the clinical features were mainly characterized by muscle hypertrophy of lower limbs, a more severe myotonia in the upper limbs compared to facial muscles, or in cases of transitory weakness, presence of mutations was first verified in CLCN1.

Cardiac Evaluation

Before starting treatment with mexiletine, the patients performed a cardiac evaluation including a 12-derivations EKG and, if necessary, a 24 h-EKG monitoring. A cardiac follow-up was performed every year.
TABLE 1 | Demographics of the cohort of patients affected by non-dystrophic myotonias.

| All the patients | RCM | DCM | NaM |
|------------------|-----|-----|-----|
| 112              | 60  | 26  | 26  |
| Not treated      | 53  | 17  | 21  |
| Treated with mexiletine | 59  | 43  | 5   |

Duration of treatment

| <1 year | 1 (7 drop-out) |
| 1–4 years (mean range: 2.5 years) | 14 (2 drop-out) |
| 4–7 years (mean range: 5.5 years) | 15 (1 drop-out) |
| >7 (until 20) years (mean range: 13.5 years) | 16 (3 drop-out) |

RCM, Recessive Congenital Myotonia; DCM, Dominant Congenital Myotonia; NaM, Myotonia due to Sodium Channel (SCN4A) Mutation.

Statistics
Average values are reported as mean ± SE. Statistical analysis was performed by using the paired Student’s t-test.

Among patients affected by recessive congenital myotonia (RCM), we found several patients carrying the same mutation. Therefore, in each specific group of patients, we compared data obtained by 3Hz-RNS as well as Chair Test, also considering the different dosage of mexiletine in the three groups.

RESULTS
Cohort Demographics
From the 112 patients affected by non-dystrophic myotonia with confirmed genetic diagnosis (55 males and 57 females, aged 2–78 years), two came from Albania, two from Romania, one from Egypt, one from Morocco, one from Guatemala, and all the others from Italy (26 from Southern, 68 from Central, and 11 from Northern Italy). The mutations in CLCN1 gene encoding the CIC-1 chloride channel were the most frequent (77%), especially the recessive ones (54%).

All the patients were offered treatment and only 52% accepted.

Mexiletine Dosage
Fifty-nine patients (33 males and 26 females) are or have been treated with mexiletine (Table 1). Until now, six of them are under 18 years and two of them are under 12. Patients under 12 are taking mexiletine at a dosage of 8 mg/Kg b.w. In adults and teenagers, the daily dosage range was between 200 and 600 mg according to clinical severity and individual needs.

Considering all the 59 treated patients, 43 (73%) were affected by recessive chloride channel myotonia (RCM), 11 (19%) had sodium channel myotonia (NaM), and five (8%) showed dominant chloride channel myotonia (DCM). Thus, 72% of all RCM patients, 19% of DCM, and 42% of NaM patients required treatment. Mexiletine treatment duration is reported in Table 1.

Adverse Effects
Mexiletine has been discontinued in 13 cases (22%), in most cases within the first months of treatment (five patients during the first month and two within the sixth month of treatment).

Within the first year of treatment, 2 patients suspended treatment because of intolerable side effects, especially dyspepsia, while one patient decided to test another drug. Within 1 and 7 years of treatment, drug suspension was observed in three other patients due to side effects or personal motivations. Regarding the treatment period of 7–20 years, three patients affected by Na channel myotonia discontinued mexiletine to test flecainide. They experienced a dramatic clinical improvement with flecainide, as hypothesized by in vitro pharmacological studies (16–19). In three pediatric cases, a galenic formulation of mexiletine using sweetening drops was necessary because of bitter taste, when dosages lower than 200 mg were requested, or in presence of difficulty in swallowing capsules.

No cardiac arrhythmias have been detected. All the reported side effects of mexiletine are summarized in Table 2.

Thus, four patients (7%) stopped mexiletine because of side effects, especially dyspepsia. Three patients (5%) shifted treatment to flecainide because of better efficacy. Five patients (8%) suspended the drug for personal motivations, while they were assuming mexiletine 200 mg/day (all these patients were affected by mild forms of myotonia and preferred not to establish a drug “addiction”), and one patient because of a gastric cancer pre-existent the treatment. In addition, four patients had to reduce daily drug doses from 600 to 400 mg/day because of the occurrence of dyspepsia.

Genotype-Phenotype Correlations
In the RCM group, the most frequent CLCN1 mutations were p.F167L (n = 15), the intronic c.180+3A>T (n = 9), and p.G190S (n = 6). Only eight patients (53%) carrying p.F167L took an anti-mytotonic treatment, while all the patients carrying c.180+3A>T or p.G190S required treatment.

TABLE 2 | Main adverse effects during mexiletine treatment.

| Number of treated patients (59) | Mexiletine side effects |
|-------------------------------|------------------------|
| 29 (49%) | No side effects |
| 25 | Dyspepsia |
| | Mild Dyspepsia (no symptomatic drugs): 17 |
| | Moderate Dyspepsia (dose limiting): 4 |
| | Severe Dyspepsia (drop-out): 4 |
| 3 | Insomnia |
| 1 | Headache |
| 1 | Dizziness |
| 1 | Diarrhea |
| 1 | Drowsiness |
| 3 | “Intolerable” bitter taste |
Likewise, all the patients carrying c.180T to G190S resulted positive to both tests. In contrast, all those carrying p.G190S resulted positive to either 3Hz-RNS or Chair Test. In the p.F167L group, only one patient resulted positive to both 3Hz-RNS and Chair Test, and only three out of 15 carried the genotype (mean standard error) showed a significant improvement during mexiletine treatment (mean standard error) in the Chair Test (unpublished data). The five patients who decided to suspend any form of symptomatic treatment within the first month can be added to the 53 patients who refused to try any treatment from the very beginning, raising the number of “skeptical or not interested to any treatment” individuals to 58 (52%) and lowering the number of “motivated to treatment” patients to 54 (48%). All the “skepticals” were mildly affected, whereas severely affected myotonic patient never refused treatment.

Not tolerated side effects were responsible for drug discontinuation in four cases (7%) and dose reduction in other four patients (7%). In particular, dyspepsia was the most frequent dose-limiting side effect, as previously reported (4, 6, 7).

We observed that patients affected by RCM requested an anti-myotonic therapy more than patients affected by NaM. This observation seems to be in contrast with literature data regarding the greater intensity of myotonia in NaM (6). However, quantification of myotonia is very difficult and no data are available about correlations between daily doses of mexiletine and the entity of myotonic phenomenon.

It could be very difficult to merge non-dystrophic myotonias in a single group of disorders, considering the variability in severity and distribution of myotonia, which primarily affects the head-neck muscles in NaM and the limb muscles in RCM/DCM. Moreover, the possible association with other signs or symptoms such as paradoxical myotonia, transitory weakness, cold sensitivity, myalgia, or episodes of paralysis, and the warm-up phenomenon, contribute to make the clinical and neurophysiologic diagnosis, as well as the quantification of myotonia severity, very challenging. For instance, there is no single neurophysiologic test available to give an objective rating to the severity of the different clinical manifestations in different patients. Similarly, the rating scales, such as SF-36 (20) and INQoL (21), giving a global evaluation of self-reported health status and impact of disease on quality of life in myotonia (4, 22–25), do not always show comparable data, possibly because of different social and cultural background (22).

**DISCUSSION**

It is worth noting that this study presents the limitations of a retrospective study and does not compare the treatment group to the non-treated patients. In addition, the population was not homogeneous due the different genes involved as well as their different mutations. Finally, the impact of myotonia on the limitation of the daily life activities is quite difficult to evaluate.

Notwithstanding, the study provides useful information on long-term mexiletine effects in a quite large cohort of myotonic patients followed up in a single center, taking also in account the rarity of these disorders. A multicenter study would allow examining a larger cohort but might also increase the risk of bias due to patients’ evaluation in different centers by different physicians.

Mexiletine was a safe drug in most of the patients, as reported in other cohorts (4, 6). None of the treated patients developed cardiac arrhythmias or other severe side effects requiring drug discontinuation. Even in a pediatric patient aged three and affected by Wolf-Parkinson-White syndrome (WPW), mexiletine proved to be safe and the girl, now aged eight, is still on therapy. Although the treated population showed a predominance of patients with chloride channel mutations on those carrying sodium channel mutations, it is unlikely that safety was influenced by the genotype. Thus, we can assume a good profile of tolerance also in patients affected by NaM.

Considering the seven patients (12%) who discontinued mexiletine within the sixth month of treatment, five cases did not report any side effect and only one patient asked for another treatment. Thus, in our experience, the most important factor affecting the use of a symptomatic therapy is the patient’s concern of taking medications “forever.” For instance, some patients adjusted the doses of mexiletine according to their physical activity. The five patients who decided to suspend any form of symptomatic treatment within the first month can be added to the 53 patients who refused to try any treatment from the very beginning, raising the number of “skeptical or not interested to any treatment” individuals to 58 (52%) and lowering the number of “motivated to treatment” patients to 54 (48%). All the “skepticals” were mildly affected, whereas severely affected myotonic patient never refused treatment.

**TABLE 3** Characterization of patients affected by recessive congenital myotonia carrying different CLCN1 mutations.

| Genotype       | F167L | G190S or 180+3A>T | F167L; G190S; 180+3A>T treated vs. untreated pts |
|----------------|-------|-------------------|--------------------------------------------------|
| Number of patients | 15    | 15                | 8 vs. 8                                          |
| Mean mexiletine dosage (mg/die) (mean standard error) | 160 (48) | 460 (48) | p < 0.001 |
| TD | −4.5 (1.6) | −58 (5.9) | p < 0.001 |
| (mean standard error) | 22.43 (4.3), n = 7 | 34.3 (3.2), n = 12 | 22.8 (3.9) vs. 33.6 |
| Chair test | 21% for the Chair Test (unpublished data). The five patients who decided to suspend any form of symptomatic treatment within the first month can be added to the 53 patients who refused to try any treatment from the very beginning, raising the number of “skeptical or not interested to any treatment” individuals to 58 (52%) and lowering the number of “motivated to treatment” patients to 54 (48%). All the “skepticals” were mildly affected, whereas severely affected myotonic patient never refused treatment.

**DISCUSSION**

It is worth noting that this study presents the limitations of a retrospective study and does not compare the treatment group to the non-treated patients. In addition, the population was not homogeneous due the different genes involved as well as their different mutations. Finally, the impact of myotonia on the limitation of the daily life activities is quite difficult to evaluate.

Notwithstanding, the study provides useful information on long-term mexiletine effects in a quite large cohort of myotonic patients followed up in a single center, taking also in account the rarity of these disorders. A multicenter study would allow examining a larger cohort but might also increase the risk of bias due to patients’ evaluation in different centers by different physicians.

Mexiletine was a safe drug in most of the patients, as reported in other cohorts (4, 6). None of the treated patients developed cardiac arrhythmias or other severe side effects requiring drug discontinuation. Even in a pediatric patient aged three and affected by Wolf-Parkinson-White syndrome (WPW), mexiletine proved to be safe and the girl, now aged eight, is still on therapy. Although the treated population showed a predominance of patients with chloride channel mutations on those carrying sodium channel mutations, it is unlikely that safety was influenced by the genotype. Thus, we can assume a good profile of tolerance also in patients affected by NaM.

Considering the seven patients (12%) who discontinued mexiletine within the sixth month of treatment, five cases did not report any side effect and only one patient asked for another treatment. Thus, in our experience, the most important factor affecting the use of a symptomatic therapy is the patient’s concern of taking medications “forever.” For instance, some patients adjusted the doses of mexiletine according to their physical activity. The five patients who decided to suspend any form of symptomatic treatment within the first month can be added to the 53 patients who refused to try any treatment from the very beginning, raising the number of “skeptical or not interested to any treatment” individuals to 58 (52%) and lowering the number of “motivated to treatment” patients to 54 (48%). All the “skepticals” were mildly affected, whereas severely affected myotonic patient never refused treatment.

Not tolerated side effects were responsible for drug discontinuation in four cases (7%) and dose reduction in other four patients (7%). In particular, dyspepsia was the most frequent dose-limiting side effect, as previously reported (4, 6, 7).

We observed that patients affected by RCM requested an anti-myotonic therapy more than patients affected by NaM. This observation seems to be in contrast with literature data regarding the greater intensity of myotonia in NaM (6). However, quantification of myotonia is very difficult and no data are available about correlations between daily doses of mexiletine and the entity of myotonic phenomenon.

It could be very difficult to merge non-dystrophic myotonias in a single group of disorders, considering the variability in severity and distribution of myotonia, which primarily affects the head-neck muscles in NaM and the limb muscles in RCM/DCM. Moreover, the possible association with other signs or symptoms such as paradoxical myotonia, transitory weakness, cold sensitivity, myalgia, or episodes of paralysis, and the warm-up phenomenon, contribute to make the clinical and neurophysiologic diagnosis, as well as the quantification of myotonia severity, very challenging. For instance, there is no single neurophysiologic test available to give an objective rating to the severity of the different clinical manifestations in different patients. Similarly, the rating scales, such as SF-36 (20) and INQoL (21), giving a global evaluation of self-reported health status and impact of disease on quality of life in myotonia (4, 22–25), do not always show comparable data, possibly because of different social and cultural background (22).
Considering all these limitations, we focused our attention on a selected group of patients affected by RCM carrying the most common CLCN1 mutations (p.F167L, c.180+3A>T, p.G190S) with the aim of evaluating the sensitivity and specificity of our clinical and neurophysiologic tests, either in the assessment of clinical severity or in monitoring the efficacy of a treatment. Thus, we compared between these patient subgroups the results of 3Hz-RNS, which indirectly evaluates transitory weakness, and the Chair Test, which estimates the motor impairment due to myotonia alone or together with transitory weakness.

In experimental functional studies, the p.F167L mutation showed little effects on chloride channel function (26–28), while p.G190S causes a severe channel dysfunction “in vitro” (28–30). Likewise, we observed that both “in vivo” tests showed better results in patients carrying p.F167L compared with those carrying p.G190S or c.180+3A>T. Accordingly, only eight patients (53%) carrying p.F167L took an anti-myotonic treatment, while all the patients carrying c.180+3A>T or p.G190S required treatment (Table 3). In addition, the treated p.F167L patients showed much better results at both neurophysiological and clinical tests.

Last but not least, mexiletine is not only safe but, in Italy, is reasonably priced and easily available for adult treatment. Some difficulties can be experienced in the pediatric setting due to the unavailability of specific formulations for this age group, requiring the use of a galenic formulation of mexiletine sweetened drops. Thus, a formulation of mexiletine alternative to the capsule as syrup or drops would be very useful, especially for pediatric patients, considering the importance of an early treatment for a correct psychomotor development. Indeed, it has been recently highlighted that SCN4A variants may determine relevant symptoms in neonates, compromising respiratory and laryngeal function, and might be associated with Sudden Infant Death Syndrome (31, 32).

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The study was carried out in compliance with Helsinki Declaration, approved by the Ethic Committee-Fondazione Policlinico Universitario A. Gemelli, Rome, Italy (ethical approved ID 3075), and all patients gave a written informed consent authorizing storage and use of clinical data and DNA samples for any clinical research purpose about their data.

AUTHOR CONTRIBUTIONS

AM drafted the manuscript for intellectual content. AD’A analyzed data concerning pediatric patients. GP analyzed data with particular attention to adult patients. FC revised the text. JD critically revised the manuscript. ML conceptualized and designed the study.

ACKNOWLEDGMENTS

We thank all patients participating to the study and the parents’ association Mia Onlus (Miotonici in Associazione), Portici, Italy. Publication fees were covered by MiA Onlus association.

REFERENCES

1. Suetterlin K, Männikkö R, Hanna MG. Muscle channelopathies: recent advances in genetics, pathophysiology and therapy, Curr Opin Neurol. (2014) 27:583–90. doi: 10.1097/WCO.0000000000000127
2. Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol. (2015) 5:761–90. doi: 10.1002/cphy.c140062
3. Phillips L, Trivedi JR. Skeletal muscle channelopathies. Neurotherapeutics. (2018) 15:954–65. doi: 10.1007/s13311-018-00678-0
4. Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonias: a randomized controlled trial. JAMA. (2012) 308:1357–65. doi: 10.1001/jama.2012.12607
5. Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, et al. Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery. Front Pharmacol. (2016) 7:121. doi: 10.3389/fphar.2016.00121
6. Suetterlin KJ, Bugiardini E, Kaski JP, Morrow JM, Matthews E, Hanna MG, et al. Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies. JAMA Neurol. (2015) 72:1531–3. doi: 10.1001/jamaneurol.2015.2338
7. Singh S, Zeltser R. Mexiletine. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing (2018).
8. Podladalo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. (1991) 39:142–8. doi: 10.1111/j.1532-5415.1991.tb01616.x
9. Hammaren E, Kjellby-Wendt G, Lindberg C. Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist. Neuromuscul Disord. (2005) 15:610–7. doi: 10.1016/j.nmd.2005.07.002
10. Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. (2004) 56:650–61. doi: 10.1002/ana.20241
11. Tan SV, Z’Graggen WJ, Boërio D, Rayan DR, Norwood F, Ruddy D, et al. Chloride channels in myotonia congenita assessed by velocity recovery cycles. Muscle Nerve. (2014) 49:845–57. doi: 10.1002/mus.24069
12. Modoni A, D’Amico A, Dallapiccola B, Mereu ML, Merlini L, Pagliarani S, et al. Low-rate repetitive nerve stimulation protocol in an Italian cohort of patients affected by recessive myotonia congenita. J Clin Neurophysiol. (2011) 28:39–44. doi: 10.1097/WNP.0b013e31820510d7
13. Lo Monaco M, D’Amico A, Luigetti M, Desaphy JF, Modoni A. Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita. Clin Neurophysiol. (2015) 126:399–403. doi: 10.1016/j.clinph.2014.06.008
14. Aminoff MJ, Layzer RB, Satya-Murti S, Faden AI. The declining electrical response of muscle to repetitive nerve stimulation in myotonia. Neurology. (1977) 27:812–6. doi: 10.1212/wnl.27.9.812
15. Brown CB. Muscle weakness after rest in myotonic disorders: an electrophysiological study. J Neurol Neurosurg Psychiatry. (1974) 37:1336–42. doi: 10.1136/jnnp.37.12.1336
16. Desaphy JF, De Luca A, Didonna MP, George AL Jr, Camerino Conte D. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. *J Physiol.* (2004) 554:321–34. doi: 10.1113/jphysiol.2003.046995

17. Desaphy JF, Modoni A, Lomonaco M, Camerino DC. Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. *Eur J Clin Pharmacol.* (2013) 69:1037–9. doi: 10.1007/s00228-012-1414-3

18. Desaphy J-F, Carbonara R, D’Amico A, Modoni A, Roussel J, Imbrici P, et al. Translational approach to address therapy in myotonia permanens due to a new SCNA4 mutation. *Neurology.* (2016) 86:2100–8. doi: 10.1212/WNL.0000000000002721

19. Lehmann-Horn F, D’Amico A, Bertini E, LoMonaco M, Merlini L, Nelson KR, et al. Myotonia permanens with Nav1.4-G1306E displays varied phenotypes during course of life. *Acta Myol.* (2017) 36:125–34.

20. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care.* (1992) 30:473–83. doi: 10.1097/00005650-199206000-00002

21. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). *Neurology.* (2007) 68:1051–7. doi: 10.1212/01.wnl.0000257819.47628.41

22. Trivedi JR, Bundy B, Statland B, Salajegheh M, Rayan DR, Venance SL, et al. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. *Brain.* (2013) 136:2189–200. doi: 10.1093/brain/awt133

23. Sansone VA, Ricci C, Montanari M, Apolone G, Rose M, Meola G, INQoL Group. Measuring quality of life impairment in skeletal muscle channelopathies. *Eur J Neurol.* (2012) 19:1470–6. doi: 10.1111/j.1468-1331.2012.03751.x

24. Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, et al. The non-dystrophic myotoniases: molecular pathogenesis, diagnosis and treatment. *Brain.* (2010) 133:9–22. doi: 10.1093/brain/awp294

25. Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. *Brain.* (2017) 140:2295–305. doi: 10.1093/brain/awx192

26. Zhang J, Bendahhou S, Sanguineti MC, Ptacek LJ. Functional consequences of chloride channel gene (CLCN1) mutations causing myotonia congenita. *Neurology.* (2000) 54:937–42. doi: 10.1212/WNL.5.4.937

27. Lucchiari S, Ulzi G, Magri F, Bucchia M, Corbetta F, Servida M, et al. Clinical evaluation and cellular electrophysiology of a recessive CLCN1 patient. *J Physiol Pharmacol.* (2013) 64:669–78.

28. Desaphy J-F, Gramegna G, Altamura C, Dinardo MM, Imbrici P, George AL Jr, et al. Functional characterization of CIC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes. *Exp Neurol.* (2013) 248:530–40. doi: 10.1016/j.expneurol.2013.07.018

29. Portaro S, Altamura C, Licitra N, Camerino GM, Imbrici P, Musumeci O, et al. Clinical, molecular, and functional characterization of CLCN1 mutations in three families with recessive myotonia congenita. *Neuromolecular Med.* (2015) 17:285–96. doi: 10.1007/s11040-014-9356-8

30. Altamura C, Lucchiari S, SABBANI D, Ulzi G, Comi GP, D’Ambrosio P, et al. The analysis of myotonia congenita mutations discloses functional clusters of amino acids within the CBS2 domain and the C-terminal peptide of the ClC-1 channel. *Hum Mutat.* (2018) 39:1273–83. doi: 10.1002/humu.23581

31. Matthews E, Silwal A, Sud R, Hanna MG, Manzur AY, Muntoni F, et al. Skeletal muscle channelopathies: rare disorders with common pediatric symptoms. *J Pediatr.* (2017) 188:181–5. doi: 10.1016/j.jpeds.2017.05.081

32. Männikkö R, Wong L, Tester DJ, Thor MG, Sud R, Küllmann DM, et al. Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study. *Lancet.* (2018) 391:1483–92. doi: 10.1016/S0140-6736(18)30021-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Modoni, D’Amico, Primiano, Capozzoli, Desaphy and Lo Monaco. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.